Three cohorts of patients were treated with the MEK inhibitor trametinib: cohort 1 (BRAF fusion–positive LGG), cohort 2 (NF1-related optic pathway glioma), and cohort 3 (NF1-related plexiform neurofibroma). Here, MAP2K7 is linked to plexiform neurofibroma.